Gossamer Bio was named in symbolism of the Gossamer thread, the invisible and fragile connection that binds all relationships in life. Gossamer’s name was chosen to highlight the importance of the organization’s relationships with our partners, members of our community, and of course – patients. Recognizing there is no time to give less than our best, Gossamer’s commitment to the patient community is real – our team aims to improve patient lives through meaningful advances in the development of new therapies and an unwavering commitment to supporting patient communities across the globe. 

Gossamer’s Gratitude

At Gossamer Bio, we recognize that choosing to participate in a clinical study is a big decision, requiring both time & commitment, and the Gossamer Team extends our sincerest THANK YOU to all patients who have participated in a clinical trial – without your participation, advancements in research would not be possible!

Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension (PAH) is a rare and chronic disease characterized by narrowing of the blood vessels in the lung, making it more difficult for blood to adequately flow from the heart to the lungs and disrupting one’s regular blood flow. This disruption prevents the lungs from receiving enough oxygen, putting extra strain on one’s heart, and making it harder to pump blood through the lungs and deliver oxygen.


The TORREY Study has been completed and Gossamer Bio reported topline data in December 2022, showing that seralutinib (AKA GB002) had a statistically significant impact on hemodynamics (PVR), right heart structure and function, and important biomarkers of PAH disease severity (e.g., NT-proBNP). Read more about the TORREY results here.


Learn More About Gossamer Bio’s Advocacy Partners


Expanded Access to Investigational Medicines Prior to Regulatory Approval 

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of Seralutinib for the treatment of pulmonary arterial hypertension (PAH). Our goal is to provide access to our investigational therapies at the appropriate time and in the most clinically appropriate manner for patients. 

Patients are at the center of our clinical programs designed to fully answer important scientific questions about the potential risks and benefits of our investigational drugs, and to obtain regulatory approval. 

Gossamer Bio may provide access to its investigational medicines outside of enrollment in clinical trials on a case-by-case basis. If you have questions about our programs or eligibility for our clinical trials, please feel free to contact us.

Contact Information: A treating physician may submit questions or requests regarding a patient’s eligibility for one of Gossamer Bio’s ongoing clinical trials by emailing [email protected] 

Request Procedure: Patients interested in obtaining access to a Gossamer Bio investigational therapy must do so via their physician. A licensed physician who believes their patient may benefit from access to a Gossamer Bio investigational therapy should contact us through the contact information above to make the request on behalf of the patient. 

Anticipated Timing: Gossamer Bio will acknowledge receipt of any questions or requests received from licensed physicians within ten (10) business days of receipt. Making a request does not guarantee the granting of access to an investigational drug by Gossamer Bio. 

In the U.S., physicians may find additional information regarding expanded access to investigational therapies by visiting the U.S. Food and Drug Administration website: Expanded Access: Information for Physicians

Non-U.S. physicians must follow local laws and regulations appropriate for the country originating the request. 

For information on Gossamer Bio’s clinical trials, please visit www.clinicaltrials.gov